For example, the reimbursement rate for mechlorethamine, another sterile injectable oncology drug, rose by 1, 281 percent between the first quarter of 2005 and the fourth quarter of 2007 (an average rise of 116 percent per quarter).

FORBES: How Margaret Hamburg's FDA Causes Cancer Drug Shortages